CORGENIX MEDICAL CORP/CO - 10-Q filing on 2012-11-13

STOCKHOLDERS' EQUITY (Details) (USD $)	3 Months Ended			1 Months Ended		1 Months Ended	3 Months Ended		1 Months Ended	3 Months Ended			1 Months Ended
STOCKHOLDERS' EQUITY (Details) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Common Stock	Sep. 30, 2011 Wescor Common Stock Purchase Agreement Third Tranche	Sep. 16, 2011 Wescor Common Stock Purchase Agreement Third Tranche	Sep. 30, 2012 Wescor Common Stock Purchase Agreement Third Tranche Minimum item	Sep. 30, 2012 Wescor 2011 Development Agreement	Sep. 30, 2011 Wescor 2011 Development Agreement	Jul. 31, 2011 Wescor 2011 Development Agreement Common Stock	Sep. 30, 2012 Wescor 2011 Development Agreement Common Stock	Sep. 30, 2011 Wescor 2011 Development Agreement Common Stock	Jul. 28, 2011 Wescor 2011 Development Agreement Common Stock	Jul. 31, 2011 Wescor 2011 Development Agreement Common Stock Maximum	Sep. 30, 2012 ELITech
Common Stock
Stock purchase commitment amount							$ 70,955	$ 83,767
Value of common stock issued	134,268		894	500,000
Shares of common stock issued			895,061	3,333,333						895,061	226,653
Value of common stock issued (in dollars per share)					$ 0.15							$ 0.15
Warrants issued (in shares)					1,666,667
Exercise price of warrants (in dollars per share)					$ 0.15
Number of new Corgenix assays to be created as a condition to the closing of the Third Tranche						2
Stock purchase commitment as a percentage of the amount of each monthly R & D invoice									66.70%
Period within which shares are to be purchased													30 days
R & D revenue	285,399	299,138					205,393	176,559
Accounts receivable for research and development							$ 205,393	$ 176,559
Shares committed to be purchased							473,032	558,449
Percentage of ownership interest in reporting entity														35.40%